Skip to Main Content

Paper Details

Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
J Infect Dis
5
2023
Author NameAffiliation
David A WohlUniversity of North Carolina at Chapel Hill
Eric S DaarLundquist Institute, Harbor-University of California Los Angeles Medical Center
Alexander L GreningerUniversity of Washington Medical Center
Joseph J EronUniversity of North Carolina at Chapel Hill
Judith S CurrierDavid Geffen School of Medicine, University of California Los Angeles
Judith S CurrierDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 6

Datasets

Release 1.2